Stock Analysts’ Downgrades for December, 13th (AIMT, BNS, FII, GILD, GLPG, HBAN, HBI, HINOY, NBIX, NDSN)

Stock Analysts’ downgrades for Friday, December 13th:

Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by analysts at Credit Suisse Group AG from an outperform rating to a neutral rating. The firm currently has $30.00 price target on the stock.

Bank of Nova Scotia (NYSE:BNS) (TSE:BNS) was downgraded by analysts at Credit Suisse Group AG from an outperform rating to a neutral rating.

Federated Investors (NYSE:FII) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating. JPMorgan Chase & Co. currently has $36.00 price target on the stock, down from their previous price target of $42.00.

Gilead Sciences (NASDAQ:GILD) was downgraded by analysts at Credit Suisse Group AG from a neutral rating to an underperform rating. The firm currently has $63.00 target price on the stock, down from their previous target price of $67.00.

GALAPAGOS NV/S (NASDAQ:GLPG) was downgraded by analysts at Credit Suisse Group AG from an outperform rating to a neutral rating. The firm currently has $169.00 target price on the stock, down from their previous target price of $174.00.

Huntington Bancshares (NASDAQ:HBAN) was downgraded by analysts at UBS Group AG from a buy rating to a neutral rating. The firm currently has $15.50 target price on the stock.

Hanesbrands (NYSE:HBI) was downgraded by analysts at Bank of America Corp from a neutral rating to an underperform rating. The firm currently has $13.00 price target on the stock, down from their previous price target of $16.00.

Hino Motors (OTCMKTS:HINOY) was downgraded by analysts at Credit Suisse Group AG from an outperform rating to a neutral rating.

Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by analysts at Credit Suisse Group AG from an outperform rating to a neutral rating. Credit Suisse Group AG currently has $110.00 target price on the stock.

Nordson (NASDAQ:NDSN) was downgraded by analysts at Oppenheimer Holdings Inc. from an outperform rating to a market perform rating.

Oil States International (NYSE:OIS) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating. JPMorgan Chase & Co. currently has $12.00 target price on the stock, down from their previous target price of $14.00.

Office Properties Income Trust (NASDAQ:OPI) was downgraded by analysts at Morgan Stanley from an overweight rating to an underweight rating.

Patterson-UTI Energy (NASDAQ:PTEN) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating. JPMorgan Chase & Co. currently has $6.00 price target on the stock, down from their previous price target of $7.00.

Construction Partners (NASDAQ:ROAD) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Construction Partners Inc. is an infrastructure and road construction company. It provides construction products and services to public and private sectors. The company’s services include construction of highways, roads, bridges, airports and commercial and residential sites. Construction Partners Inc. is based in Alabama, United States. “

Retail Properties of America (NYSE:RPAI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Retail Properties of America, Inc. is a real estate investment trust that owns and operates shopping centers in the United States. Its retail-operating portfolio includes power centers, community centers, neighborhood centers, lifestyle centers and single-user retail properties. The Company’s retail properties are primarily located in retail districts. Retail Properties of America, Inc. is headquartered in Oak Brook, IL. “

Victory Capital (NASDAQ:VCTR) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating. The firm currently has $22.00 price target on the stock, up from their previous price target of $21.00.

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.